BioSpace News Archive

STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company —a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them rather than using electricity.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for the treatment of Duchenne muscular dystrophy.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”), a biotechnology company pioneering its patented Botanical Synthesis

FibroBiologics, Inc. a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2023, with the U.S. Securities and Exchange Commission.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2023.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 5 individuals hired by Sarepta in February 2024.

DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen’s Health Care Conference 2024 on Monday, March 4, 2024, at 11:10 a.m. EST.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023.

Know Labs, Inc. announced it has entered into a funding agreement for an investment of up to $12 million, of which it has executed a $4 million close with Lind Global Fund II LP, an investment entity managed by The Lind Partners, a New York-based institutional fund manager.